cryptocurrency report Top Top stories

Shanghai's announcement of the action plan for mergers and acquisitions of listed companies is indeed a heavy news. However, can this still retain the retail investors who were hurt by the market on Tuesday? On Tuesday, A shares opened higher and fell back, which triggered a crisis of confidence in the market to some extent. So, shall we go or stay? Let me express my personal views.The action plan can be called a heavy release in Shanghai, and I will simply classify the main contents.Just when everyone was still sick, A-shares ushered in good news. Shanghai issued the "Shanghai Action Plan to Support the Merger and Reorganization of Listed Companies (2025-2027)". Is this to retain injured retail investors? Next, let's discuss it in detail.

First, Tuesday's market rally was really disgusting to everyone, but the good thing was to cover the gap of the day's upward gap and rule out the hidden danger of covering the gap in the market outlook.From the above four points of view, I think I will stay. As long as the upward trend of A shares is still there, I will not leave easily, so I can grasp the rhythm of high selling and low sucking.It is worth noting that the action plan ranks biomedicine in the second place, and sets up a 10 billion biomedical industry M&A fund, which is basically the same as the status of integrated circuits. In addition, the action plan puts the merger of securities companies at the end, and its status has declined.

Just when everyone was still sick, A-shares ushered in good news. Shanghai issued the "Shanghai Action Plan to Support the Merger and Reorganization of Listed Companies (2025-2027)". Is this to retain injured retail investors? Next, let's discuss it in detail.The action plan can be called a heavy release in Shanghai, and I will simply classify the main contents.Second, the key areas mainly involve integrated circuits, biomedicine, new materials and other industries. Make good use of the 10 billion yuan integrated circuit design industry M&A fund and set up a 10 billion yuan biomedical industry M&A fund;